Manish Kohli, Director and Physician Scientist Training Program University of Utah Health, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Our multidisciplinary team has developed plasma cell-free DNA (cfDNA) methylation-based prognostic models for metastatic castration-resistant prostate cancer (mCRPC).
This work demonstrates how tumor-biology driven risk scores, when integrated with clinical prognostic factors, can be applied as individualized nomograms to enhance the definition of ‘lethal prostate cancer.’ These models outperform conventional biomarkers that often fail to capture poor-prognosis disease biology.
A special congratulations to Jodie Wang for her first authorship during her PhD training on this effort, and heartfelt thanks to all members of the Liang Wang Lab and Aik Choon Tan Lab for their invaluable contributions to this collaborative effort.”
Title: Plasma cell-free DNA methylation-based prognosis in metastatic castrate-resistant prostate cancer
Authors: Jodie Wong, Yijun Tian, Manishkumar S. Patel, Kapil Avasthi, Claire Hanson, Matt Larsen, Enos Ampaw, Rebekah Gutowski, Muhammad Z. H. Fadlullah, Joseph Finkelstein, Aik Choon Tan, Jong Park, Brandon J. Manley, Chiang-Ching Huang, Manish Kohli, Liang Wang
Read the Full Article at Precision Oncology.
Read more posts featuring Manish Kohli on OncoDaily.